(Hypertension. 1997;30:928-933.)
© 1997 American Heart Association, Inc.
Articles |
From the Departments of Medicine, The University of Texas Health Science Center, Houston (A.M.K., A.H., T.S.), and Baylor College of Medicine (J.C.A.), Houston, Tex.
Correspondence to Andrew M. Kahn, MD, 4.138 MSB, University of Texas Health Science Center, PO Box 20708, Houston, TX 77225.
| Abstract |
|---|
|
|
|---|
Key Words: serotonin cyclic GMP fura-2 Ca2+ transport arginine
| Introduction |
|---|
|
|
|---|
Several investigators have reported that insulin dilates human VSM in vivo by a NOS-dependent mechanism.10 11 We and others have reported that insulin acutely (within 30 minutes) decreases the contractile agonist-induced Ca2+i transient and contraction of endothelial cellfree cultured VSM cells.7 12 13 14 Since VSM cells contain NOS in certain circumstances,15 we wished to test the hypothesis that these effects of insulin in cultured VSM cells are dependent on NOS activity. We report here that insulin acutely attenuates 5-HTinduced Ca2+ influx and contraction of endothelial cellfree cultured VSM cells by an NOS-dependent pathway.
| Methods |
|---|
|
|
|---|
Primary confluent cultures of these cells were also prepared, as previously described.17 The dispersed cells were pelleted as described above and suspended in complete DMEM, which contained 10% fetal calf serum, 1% glutamine, and 1% penicillin-streptomycin solution. The cell suspension was adjusted to 1.7x106 cells/mL, and 0.3 mL was placed on the surface of 10x22-mm glass coverslips. Alternatively, the cell suspension was adjusted to 2x105 cells/mL, and 1 mL was placed in 35-mm plastic culture dishes. The coverslips and dishes were placed in a humidified tissue culture incubator maintained at 37°C and equilibrated with 5% CO2/95% air. After 72 hours and every 72 hours thereafter, the media were replaced with 1 mL of fresh complete DMEM. The cells reached confluence between days 10 and 15, when they were used. The identity of the confluent cultured cells as smooth muscle cells was confirmed as previously described by the "hill-and-valley" pattern of cell growth and by a ratio of actin to myosin heavy chain characteristic of intact VSM.16
Fura-2 Fluorescence
To assess the activity of Ca2+ influx pathways, we
took advantage of the facts that Mn2+ can enter cells via
Ca2+ influx pathways in many cell types, including VSM
cells, and that once inside the cells, Mn2+ quenches fura-2
fluorescence.18 When the cells are exposed to
extracellular Mn2+ and excited at a
Ca2+-insensitive wavelength, a fall in fluorescence
indicates Mn2+ influx irrespective of any possible changes
in Ca2+i.18 We previously used
this technique to assess the activities of Ca2+ influx
pathways in these VSM cells.17 Cells on coverslips were
preincubated with 2.4 µmol/L fura-2-AM (Molecular Probes)
that had been sonicated for 20 seconds in DMEM with 0.1% bovine serum
albumin. A coverslip was placed in a quartz cuvette inside a
fluorescent spectrophotometer (Perkin-Elmer LS-3B) such that
the coverslip was anchored at its bottom and top and sat at a 45°
angle to the excitation beam. The cuvette (2 mL), which was held in a
thermostatted holder, was superfused with PSS at 37°C. A peristaltic
perfusion pump delivered solution at 3 mL/min into the bottom of the
cuvette via a glass capillary tube that ran on the opposite side of the
coverslip from the excitation light and pumped solution at 3 mL/min
from the top of the cuvette. The half-time for the turnover of solution
in the cuvette was 0.46 minute. The storage flasks of solutions were
kept at 37°C. The coverslip was superfused for 30 minutes at 37°C
at 1 mL/min with PSS that contained (in mmol/L) 140 NaCl, 4
KCl, 1.8 CaCl2, 0.8 MgSO4, 5 glucose, and
10 HEPES-Tris, pH 7.4, plus 0.1% bovine serum albumin.
The coverslip was then superfused with nominally
Ca2+-free solution (PSS without CaCl2) at 3
mL/min and excited through a 10-nm slit width at 362 nm, which is the
Ca2+-insensitive (isosbestic) wavelength for
fura-2.17 The emission at 510 nm was continuously measured
through a 10-nm slit width. When a stable value was obtained, 0.5
mmol/L MnCl2 was added to the superfusion solution,
followed by the same solution with 10-5
mol/L 5-HT, as previously described.17 The rate of
fluorescence quenching was taken as an estimate of
Mn2+ influx. To standardize this rate from coverslip to
coverslip, the superfusion solution was changed again to nominally
Ca2+-free PSS containing 5 mmol/L
MnCl2 plus 2.5 µmol/L ionomycin. This
ionophore rapidly allowed Mn2+ influx and quenched the
fluorescence to a stable basal value. The difference between
this value and the initial stable value before the cells were exposed
to Mn2+ was taken as 100 arbitrary fluorescence
units, as previously described.17
cGMP Assay
Dishes of confluent VSM cells were preincubated in PSS at 37°C
for 30 minutes. The media were changed to PSS with 0.5
mmol/L IBMX, and the cells were harvested 5 minutes later by
adding 1 mL of ice-cold PSS containing 65% ethanol. The extract was
centrifuged at 10 000g for 15 minutes at 4°C and
the supernatant evaporated to dryness in a Speed Vac SC100 (Savant).
cGMP content of acetylated samples was measured with the cGMP
[125I] Assay System (Amersham).
Thin-Layer Chromatography Analysis of
Citrulline Production
Dishes of confluent cells were incubated with 1 mL PSS
containing 5 µmol/L L-arginine and 0.2 µCi
14C-L-arginine (Amersham) for 4 hours at
37°C. Miconozole (75 µmol/L) was present to
prohibit citrulline production by the P450 system. The
incubation solution was discarded and the cells were
homogenized in 0.4 mL deionized water. The
homogenate was centrifuged at 10 000g
for 10 minutes at 4°C and the supernatant evaporated to dryness in a
Speed Vac SC 100. The residue was resuspended in 25 µL deionized
water containing 2 mg/mL L-arginine plus 2
mg/mL L-citrulline and applied to silica gel 60
plates, 20x20 cm, aluminum (Whatman). A solvent system containing
CHCl3/CH3OH/NH4OH/H2O,
1:4:2:1 (vol/vol) was used. Relative front for arginine and
citrulline was 0.49 and 0.81, respectively, as determined by
autoradiography of authentic
14C-L-arginine and
14C-L-citrulline standards. The location of
arginine and citrulline was confirmed by staining with ninhydrin spray.
The amounts of 14C-arginine and 14C-citrulline
associated with the incubated cells were determined by liquid
scintillation spectroscopy. The percentage of 14C-arginine
that was converted to 14C-citrulline was calculated and
corrected for the percentage of the 14C-arginine stock
contaminated with 14C-citrulline (about 1%, determined in
each experiment by thin-layer chromatography, as
described above). Each experiment was performed in triplicate.
Cell Contraction
After 5 to 8 days of culture, the cells grown on the collagen
gels were used for contraction studies, as previously
described.7 The dishes were placed on the heated (37°C)
stage of a Nikon Diaphot inverted phase-contrast microscope, and the
culture medium was replaced with PSS. After a 30-minute preincubation
period, a field of at least 6 to 10 cells was photographed at 200x to
obtain baseline images. The medium was replaced with the same
experimental solution containing 10-5
mol/L 5-HT, and after 10 minutes another photograph was taken of
the same field.
Bovine insulin and 5-HT were obtained from Sigma. Statistical analysis was performed on paired data by use of Student's t test and ANOVA with multiple comparisons using the Newman-Keuls test. Statistical significance was set at P<.05.
| Results |
|---|
|
|
|---|
|
If this process depends on VSM NOS activity, L-NMMA, an
inhibitor of NOS, should inhibit the stimulation of cGMP
production by insulin. This was found to be the case. As shown
in Fig 2
, when compared with control
cells, 0.1 mmol/L L-NMMA significantly decreased cGMP
production, and insulin plus 5-HT significantly increased it.
When compared with insulin plus 5-HT, the addition of L-NMMA
significantly inhibited cGMP production to a level not
different from L-NMMA alone. These data suggest that insulin plus 5-HT
stimulates cGMP production in an NOS-dependent manner.
|
Citrulline Production
NOS converts arginine to citrulline and nitric oxide. To verify
that these cells have functional NOS, dishes of cells were incubated
with 5 µmol/L 14C-arginine, and the amount of
14C-citrulline produced was measured in both the presence
and absence of 0.1 mmol/L L-NMMA. In the absence of L-NMMA
(control), the cells took up an average of 620 pmol arginine/mg protein
per hour of which 1.70±0.31% was converted to citrulline (n=4). In
the presence of L-NMMA, 14C-arginine uptake was 97±8% of
the amount taken up without L-NMMA (n=4, NS). The percentage of
14C-arginine taken up in the presence of L-NMMA that was
converted to citrulline was 0.68±0.21% (n=4, P<.05 versus
control). These data suggest that the cells have functional NOS since
they convert arginine to citrulline by a L-NMMA-inhibitable
mechanism.
Cell Contraction
Since we had previously shown that insulin inhibited
5-HTstimulated Ca2+ influx and contraction of these VSM
cells,7 17 we wished to determine whether these effects
are dependent on VSM NOS by determining whether inhibitors
of NOS blunted these actions of insulin. As shown in Fig 3
, 1
nmol/L insulin inhibited
5-HTinduced contraction of individual VSM cells. L-NMMA (0.1
mmol/L) alone did not affect 5-HTinduced contraction, but it
eliminated insulin's ability to inhibit contraction. As shown in Fig 3
, dibutyryl cGMP inhibited contraction in these cells, as is the case
for VSM in general.19 To rule out the possibility that
L-NMMA nonspecifically negates the action of all
in- hibitors of VSM contraction, we determined whether
L-NMMA would blunt the inhibition of VSM contraction by nitroprusside,
an agent that donates nitric oxide to the VSM cell independently of NOS
activity.20 As also shown in Fig 3
, 0.1 mmol/L
nitroprusside inhibited VSM contraction, and L-NMMA did not alter this
effect. L-NMMA competes with L-arginine as a substrate for
NOS and inhibits the enzyme's activity.21 In order to
demonstrate further the specificity of L-NMMA to block insulin's
inhibition of VSM contraction, we determined whether a 10-fold excess
of L-arginine would prevent 0.1 mmol/L L-NMMA
from blunting insulin's inhibition of 5-HTinduced contraction. As
shown in Fig 3
, 1
mmol/L L-arginine alone did
not affect insulin-inhibited contraction. Fig 3
also shows that
0.1 mmol/L L-NMMA did not blunt the inhibition of
contraction by insulin in the presence of this large concentration of
L-arginine. Taken together, the data in Fig 3
indicate that
insulin inhibits 5-HTinduced contraction of VSM by an NOS-dependent
mechanism.
|
To demonstrate further that the inhibition of 5-HTstimulated
contraction by insulin was dependent on NOS, we determined whether
another NOS inhibitor, L-NAME, could inhibit this effect of
insulin.21 As shown in Fig 4
, 0.1 mmol/L L-NAME alone
did not affect 5-HTinduced VSM contraction, but it prevented
insulin's inhibition of 5-HTinduced contraction. The fact that two
different inhibitors of NOS (L-NMMA, L-NAME) block
insulin's ability to attenuate 5-HTinduced VSM cell contraction
supports the view that this effect of insulin is dependent on NOS
activity.
|
We predicted that insulin would have no effect on contraction if the
cells had been previously depleted of BH4, an essential
cofactor for NOS activity.15 21 BH4 is
produced by the enzyme GTP cyclohydrolase I.15 It has
previously been demonstrated that prolonged treatment of VSM cells with
DAHP, an inhibitor of GTP cyclohydrolase I, depletes cells
of BH4.22 As shown in Fig 5
, insulin inhibits 5-HTinduced
contraction of control cells. When the cells had been preincubated for
30 minutes or 18 hours with DAHP, 5-HTinduced contraction was not
affected. However, as also shown in Fig 5
, insulin no longer inhibited
5-HTinduced contraction of cells after 18 hours of preincubation with
DAHP. This suggests that an adequate level of BH4 is
necessary for insulin to inhibit VSM contraction. As also shown in Fig 5
, a relatively brief 30-minute preincubation of cells with DAHP did
not blunt insulin's effect. This finding tends to rule out the
possibility that the prolonged exposure to DAHP did not merely blunt
insulin's action by a nonspecific effect, but that the drug's effect
to deplete the cells of BH4 was required to block
insulin's ability to inhibit VSM contraction. These data further
support the notion that the acute effect of insulin to inhibit
contraction is dependent on NOS activity.
|
Mn2+ Influx Rate
We have previously demonstrated that insulin inhibits both
5-HTinduced Ca2+ influx and contraction in these VSM
cells.7 17 The former effect of insulin resulted in a
blunted 5-HTinduced Ca2+i transient that
presumably contributed to insulin's inhibition of
contraction.17 The data in Figs 3 through 5![]()
![]()
indicate that
insulin-inhibited contraction is dependent on VSM NOS activity, and the
data in Figs 1
and 2
suggest that insulin stimulates cGMP
production by 5-HTtreated cells via an NOS-dependent pathway.
Since others have reported that cGMP inhibits Ca2+ channels
in VSM,23 24 25 we predicted that L-NMMA would block
insulin's inhibition of 5-HTstimulated Ca2+ influx. We
assessed Ca2+ influx by measuring the rate of quenching of
intracellular fura-2 fluorescence by extracellular
Mn2+. We determined whether L-NMMA would eliminate
insulin's ability to reduce the 5-HTstimulated rate of quenching of
fura-2 fluorescence, which we had previously
shown.17 As shown in Fig 6
, the basal rate of fura-2 quenching by Mn2+ was not affected
by insulin or L-NMMA. When the cells were exposed to 5-HT, the rate of
fura-2 fluorescence quenching was increased and insulin
inhibited that effect. We have previously reported these findings,
which indicated that 5-HT stimulates Ca2+ influx by an
insulin-inhibited mechanism.17 As also shown in Fig 6
, L-NMMA alone did not affect the 5-HTstimulated rate of fura-2
quenching, but insulin no longer inhibited this rate in the presence of
L-NMMA. These data indicate that insulin-inhibited Ca2+
influx was also dependent on VSM NOS activity.
|
| Discussion |
|---|
|
|
|---|
The present data also show that insulin inhibits 5-HTstimulated Mn2+ (a surrogate for Ca2+) influx and inhibits contraction of these cells in a L-NMMAinhibitable and BH4-dependent manner. L-NAME, another inhibitor of NOS, also blocked insulin's inhibition of 5-HTinduced contraction. L-NMMA did not affect the inhibition of contraction by nitroprusside, a direct NO donor, and it did not block insulin's inhibition of contraction in the presence of 10-fold excess L-arginine. Taken together, the present data demonstrate that the inhibition of 5-HTinduced VSM contraction by insulin is dependent on NOS in the VSM cell itself.
This study does not determine which isoform or isoforms of NOS are responsible for the present findings. Since 5-HT alone increases Ca2+i in these cells but does not by itself increase the production of cGMP, the NOS in these cells must not be a Ca2+-sensitive isoform such as the constitutive NOS found in endothelial cells or neurons.15 21 The fact that insulin blunts the 5-HTinduced Ca2+ transient in these cells7 yet increases the production of cGMP by 5-HTtreated cells supports further the notion that a Ca2+-sensitive NOS was not responsible for these findings. Indeed, a Ca2+-sensitive NOS (cNOS) has not been found in VSM,15 but an iNOS has been described in this tissue. It seems that a VSM iNOS is likely to be responsible for the present findings. Although VSM iNOS has usually been identified after exposing the tissue to various cytokines for several hours, other investigators have demonstrated the presence of iNOS in VSM cells that had not been treated with such agents.26 27 28 29 Since the time course of insulin's effects was acute (30 minutes), it is unlikely that insulin-induced NOS transcription and translation were responsible for the present findings.
The present studies are consistent with previous reports of the relationship between insulin, NOS, and cGMP in VSM. Saito et al reported that insulin inhibited the angiotensin IIinduced Ca2+i transient in cultured rat VSM cells by a L-NMMAsensitive pathway.12 Trovati et al reported that insulin stimulated cGMP production in human cultured VSM cells by a L-NMMAdependent mechanism.30 Thus, the present report is consistent with these prior studies and extends the known relationships between insulin and VSM NOS, cGMP, and Ca2+i to the inhibition of VSM contraction.
We demonstrated previously that the inhibition of Ca2+ influx and contraction of individual primary cultured VSM cells by insulin is dependent on insulin-induced glucose uptake.31 Intracellular glucose is converted in part to diacylglycerol, and high extracellular glucose concentration has been linked to diacyglyerol production and activation of protein kinase C in VSM.32 33 Although speculative, it is possible that insulin-induced glucose transport caused a rise in intracellular diacylglycerol concentration, and that when coupled to a 5-HTinduced rise in Ca2+i, activated one or more Ca2+-sensitive isoforms of protein kinase C in the VSM cell. Increased protein kinase C activity might acutely stimulate iNOS activity in the VSM cell by posttranslational modification. Preliminary data from our laboratory have shown that raising Ca2+i with ionomycin does not stimulate cGMP production in these VSM cells, but the addition of insulin to ionomycin-treated cells stimulates cGMP production by 44%.34 Thus, we hypothesize that other contractile agonists that raise Ca2+i in VSM cells, such as angiotensin II or norepinephrine, would also cause an insulin-induced increase in guanylate cyclase activity. Additional research is needed to test this hypothesis.
Alternatively, the present data are also consistent with
the possibility that insulin increases cGMP production and
inhibits VSM contraction by a mechanism that requires only a permissive
role of NOS but that is not dependent on stimulation of NOS activity by
insulin. Indeed, others have shown that
2-adrenoceptor
agonistinduced vasodilation of rat middle cerebral
artery,35 and whole body heating-induced vasodilation of
rabbit ear artery36 are dependent on the permissive
presence of nitric oxide production by NOS, but their
mechanisms for vasodilation are not by increasing NOS activity. Further
research is necessary to determine the precise mechanisms by which
insulin-inhibited VSM contraction is dependent on VSM NOS activity.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received February 12, 1997; first decision February 26, 1997; accepted February 26, 1997.
| References |
|---|
|
|
|---|
2. Laakso M, Edelman SV, Brechtel G, Baron AD. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes. 1992;41:1076-1083.[Abstract]
3. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. J Clin Invest. 1990;85:1844-1852.
4.
Doria A, Fioretto P, Avogaro A, Carraro A, Morocufti
A, Trevisan R, Frigato F, Crepaldi G, Viberti G, Nosadini R.
Insulin resistance is associated with high sodium-lithium
countertransport in essential hypertenison. Am J
Physiol. 1991;261:E684-E691.
5.
Baron AD. Hemodynamic actions
of insulin. Am J Physiol. 1994;267:E187-E202.
6. Zemel MB, Reddy S, Sowers JR. Insulin attenuation of vasoconstrictor responses to phenylephrine in Zucker lean and obese rats. Am J Hypertens. 1991;4:537-539.[Medline] [Order article via Infotrieve]
7.
Kahn AM, Seidel CL, Allen JC, O'Neil RG, Shelat H,
Song T. Insulin reduces contraction and intracellular calcium
concentration in vascular smooth muscle.
Hypertension. 1993;22:735-742.
8. Feldman RD, Bierbrier GS. Insulin-mediated vasodilation: impairment with increased blood pressure and body mass. Lancet. 1993;342:707-709.[Medline] [Order article via Infotrieve]
9.
Anderson EA, Mark AL. The vasodilator action of
insulin: implications for the insulin hypothesis of
hypertension. Hypertension. 1993;21:136-141.
10. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. J Clin Invest. 1994;94:1172-1179.
11. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 1994;94:2511-2515.
12. Saito F, Hori MT, Fittingott M, Hino R, Tuck ML. Insulin attenuates agonist-mediated calcium mobilization in cultured rat vascular smooth muscle cells. J Clin Invest. 1993;92:1161-1168.
13. Standley PR, Zhang F, Ram JL, Zemel MB, Sowers JR. Insulin attenuates vasopressin-induced calcium transients and a voltage-dependent calcium response in rat vascular smooth muscle cells. J Clin Invest. 1991;88:1230-1236.
14. Touyz RM, Tolloczko B, Schiffrin EL. Insulin attenuates agonist-evoked calcium transients in vascular smooth muscle cells. Hypertension. 1994;23(suppl I):I-23-I-28.
15. Schini-Kerth VB, Vanhoutte PM. Nitric oxide synthases in vascular cells. Exp Physiol. 1995;80:885-905.[Medline] [Order article via Infotrieve]
16.
Seidel CL, White V, Wallace C, Amann J, Dennison D,
Schildmeyer LA, Vu F, Allen JC, Navarro L, Eskin S. Effect of
seeding density and time in culture on vascular smooth muscle cell
proteins. Am J Physiol. 1988;254:C235-C242.
17.
Kahn AM, Allen JC, Seidel CL, Song T. Insulin
inhibits serotonin-induced Ca2+ influx in
vascular smooth muscle. Circulation. 1994;90:384-390.
18. Chen XL, Rembold CM. Cyclic nucleotide-dependent regulation of Mn2+ influx, [Ca2+]i, and arterial smooth muscle relaxation. Am J Physiol. 1992;254:C468-C473.
19. Lincoln TM, Komalavilas P, Cornwell TL. Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase. Hypertension. 1994;23(pt 2):1141-1147.
20.
Kowaluk EA, Seth P, Fung H-L.
Metabolic activation of sodium nitroprusside to nitric
oxide in vascular smooth muscle. J Pharmacol Exp
Ther. 1992;262:916-922.
21.
Nathan C, Xie Q. Regulation of biosynthesis of
nitric oxide. J Biol Chem. 1994;269:13725-13728.
22. Scott-Burden T, Elizondo E, Ge T, Boulanger C, Vanhoutte P. Simultaneous activation of adenylyl cyclase and protein kinase C induces production of nitric oxide by vascular smooth muscle cells. Mol Pharmacol. 1994,46:274-282.
23. Godfraind T. EDRF and Cyclic GMP control gating of receptor-operated calcium channels in vascular smooth muscle. Eur J Pharmacol. 1986;126:341-343.[Medline] [Order article via Infotrieve]
24.
Ishikawa T, Hume JR, Keef KD. Regulation of
Ca2+ channels by cAMP and cGMP in vascular smooth
muscle cells. Circ Res. 1993;73:1128-1137.
25.
Lorenz JN, Bielefeld DR, Sperelakis N.
Regulation of calcium channel current in A7r5 vascular smooth muscle
cells by cyclic nucleotides. Am J
Physiol. 1994;266:C1656-C1663.
26. Mohaupt MG, Elzie JL, Ahn KY, Clapp WL, Wilcox CS, Kone BC. Differential expression and induction of mRNAs encoding two inducible nitric oxide synthases in rat kidney. Kidney Int. 1994;46:653-665.[Medline] [Order article via Infotrieve]
27. Tojo A, Gross SS, Zhang L, Tisher CC, Schmidt HHW, Wilcox CS, Madsen KM. Immunocytochemical localization of distinct isoforms of nitric oxide synthase in the juxtaglomerular apparatus of normal rat kidney. J Am Soc Nephrol. 1994;4:1438-1447.[Abstract]
28.
Schini VB, Vanhoutte PM. L-arginine
evokes both endothelium-dependent and -independent
relaxations in L-argininedepleted aortas of the
rat. Circ Res. 1991;68:209-216.
29. Wood KS, Buga GM, Byrns RE, Ignarro LJ. Vascular smooth muscle-derived relaxing factor (MDRF) and its close similarity to nitric oxide. Biochem Biophys Res Commun. 1990;170:80-88.[Medline] [Order article via Infotrieve]
30. Trovati M, Massucco P, Mattiello L, Cavalot F, Mularoni E, Hahn A, Anfossi G. Insulin increases cyclic nucleotide content in human vascular smooth muscle cells: a mechanism potentially involved in insulin-induced modulation of vascular tone. Diabetologica. 1995;38:936-941.[Medline] [Order article via Infotrieve]
31.
Kahn AM, Lichtenberg RA, Allen JC, Seidel CL, Song
T. Insulin-stimulated glucose transport inhibits
Ca2+ influx and contraction in vascular smooth
muscle. Circulation. 1995;92:1597-1603.
32.
Lee IS, Saltsman KA, Ohashi H, King GL.
Activation of protein kinase C by elevation of glucose concentration:
Proposal for a mechanism in the development of diabetic vascular
complications. Proc Natl Acad Sci U S A. 1989;86:5141-5145.
33. Williams B, Schrier RW. Characterization of glucose-induced in situ protein kinase C activity in cultured vascular smooth muscle cells. Diabetes. 1992;41:1464-1472.[Abstract]
34. Kahn A, Song T. Insulin acutely stimulates inducible nitric oxide synthase (iNOS) activity in cultured vascular smooth muscle (VSM) cells which inhibits their contraction. J Am Soc Nephrol. 1996;7:1565. Abstract.
35.
Bryan RM, Steenberg ML, Eichler MY, Johnson TD,
Swafford MWG, Suresh MS. Permissive role of NO in
2-adrenoceptor-mediated dilations in rat cerebral
arteries. Am J Physiol. 1995;269:H1171-H1174.
36.
Farrell DM, Bishop VS. Permissive role for
nitric oxide in active thermoregulatory vasodilation in rabbit
ear. Am J Physiol. 1995;269:H1613-H1618.
This article has been cited by other articles:
![]() |
J. H. Lee, T. Palaia, and L. Ragolia Impaired insulin-mediated vasorelaxation in diabetic Goto-Kakizaki rats is caused by impaired Akt phosphorylation Am J Physiol Cell Physiol, February 1, 2009; 296(2): C327 - C338. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Lee, S. Xia, and L. Ragolia Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R144 - R154. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon Cardiovascular Actions of Insulin Endocr. Rev., August 1, 2007; 28(5): 463 - 491. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Lee and L. Ragolia AKT phosphorylation is essential for insulin-induced relaxation of rat vascular smooth muscle cells Am J Physiol Cell Physiol, December 1, 2006; 291(6): C1355 - C1365. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. B. Okon, A. W.Y. Chung, P. Rauniyar, E. Padilla, T. Tejerina, B. M. McManus, H. Luo, and C. van Breemen Compromised Arterial Function in Human Type 2 Diabetic Patients Diabetes, August 1, 2005; 54(8): 2415 - 2423. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yang, Y. Yang, S. Zhang, and A. M. Kahn Insulin-Stimulated Hydrogen Peroxide Increases Guanylate Cyclase Activity in Vascular Smooth Muscle Hypertension, October 1, 2003; 42(4): 569 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Clark, M. G. Wallis, E. J. Barrett, M. A. Vincent, S. M. Richards, L. H. Clerk, and S. Rattigan Blood flow and muscle metabolism: a focus on insulin action Am J Physiol Endocrinol Metab, February 1, 2003; 284(2): E241 - E258. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Kahn, J. C. Allen, C. L. Seidel, D. S. Lichtenberg, T. Song, and S. Zhang Insulin increases NO-stimulated guanylate cyclase activity in cultured VSMC while raising redox potential Am J Physiol Endocrinol Metab, April 1, 2000; 278(4): E627 - E633. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Kahn, J. C. Allen, C. L. Seidel, and S. Zhang Insulin Inhibits Migration of Vascular Smooth Muscle Cells With Inducible Nitric Oxide Synthase Hypertension, January 1, 2000; 35(1): 303 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Claxton, M. W. Brands, S. M. Fitzgerald, and J. A. Cameron Inhibition of Nitric Oxide Synthesis Potentiates Hypertension During Chronic Glucose Infusion in Rats Hypertension, January 1, 2000; 35(1): 451 - 456. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Cohen The potential clinical impact of 20 years of nitric oxide research Am J Physiol Heart Circ Physiol, April 1, 1999; 276(4): H1404 - H1407. [Full Text] [PDF] |
||||
![]() |
A. M. Kahn, A. Husid, T. Odebunmi, J. C. Allen, C. L. Seidel, and T. Song Insulin inhibits vascular smooth muscle contraction at a site distal to intracellular Ca2+ concentration Am J Physiol Endocrinol Metab, May 1, 1998; 274(5): E885 - E892. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Z. XUE, W. O. WILKISON, R. L. MYNATT, N. MOUSTAID, M. GOLDMAN, and M. B. ZEMEL The agouti gene product stimulates pancreatic {beta}-cell Ca2+ signaling and insulin release Physiol Genomics, July 15, 1999; 1(1): 11 - 19. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |